VK2735 Development Programs - VANQUISH Phase 3 program is underway for VK2735, a GLP-1/GIP dual agonist for obesity[7, 67] - VENTURE Oral Phase 2 obesity study for VK2735 Oral, a GLP-1/GIP dual agonist, successfully achieved its primary endpoint[7, 10] - An Amylin agonist for obesity has an IND planned for 1Q26[7, 8] - VK2809, a selective thyroid receptor-β agonist for MASH, reported successful Phase 2b data in 2Q24[7, 8] - VK0214, a selective thyroid receptor-β agonist for X-ALD, reported successful Phase 1b data in 4Q24[7, 8] VK2735 Oral Phase 1 Study Results - After 28 days of oral dosing, up to 8.2% reduction in body weight was observed[22] - At 100 mg dose, up to approximately 7% placebo-adjusted weight loss was observed[15] - Weight loss effects were largely maintained through Day 57, four weeks from the last study dose[20] VK2735 VENTURE Oral Phase 2a Study Results - Up to 12.2% reduction from baseline in body weight was observed after 13 weeks[29, 32, 48] - A statistically significant difference vs placebo was observed at all time points for doses >15 mg[34] - In an exploratory maintenance cohort, down-titration from 90mg to 30mg produced continued gradual weight loss through Week 13[42] VK2735 Subcutaneous Formulation VENTURE Phase 2 Study Results - Up to 14.7% mean weight loss was observed after 13 weeks of VK2735 treatment[55, 66] - In the MAD study, a dose-dependent improvement in weight loss of up to 7.8% (6% placebo-adjusted) was reported after 28 days in subjects with BMI ≥30[50] Financial Information - As of September 30, 2025, the company had $714.57 million in cash and short-term investments[74] - Cash burn year-to-date as of September 30, 2025, was $188.042 million[74]

VK2735 (GLP-1/GIP Dual Agonist) for Obesity - The VENTURE Phase 2 obesity study achieved its primary endpoint, demonstrating a significant reduction in body weight after 13 weeks of treatment[7, 43] - In the VENTURE study, patients receiving VK2735 experienced up to a 14.7% reduction in body weight from baseline after 13 weeks[44, 61] - Up to 88% of patients in the VENTURE study experienced ≥10% weight loss at the 15mg dose after 13 weeks[50, 51] - Oral VK2735 Phase 1 study showed a dose-dependent reduction in body weight, with a significant reduction of 5.3% versus placebo at the highest dose after 28 days[74, 97] - The company plans to initiate a Phase 2 trial for oral VK2735 in obesity in the second half of 2024[7, 98] VK2809 (Selective Thyroid Receptor-β Agonist) for NASH/MASH - The VOYAGE Phase 2b trial achieved its primary endpoint, demonstrating a robust reduction in liver fat[7, 125] - In the VOYAGE study, patients experienced up to a 55% median reduction in liver fat at 12 weeks[113, 114] - Up to 85% of VK2809 patients experienced a response, defined as a ≥30% decrease in liver fat at Week 12 in the VOYAGE study[116, 117] VK0214 (Selective Thyroid Receptor-β Agonist) for X-ALD - VK0214 Phase 1 study demonstrated LDL-C reductions, with data indicating approximately a 20% reduction from baseline[136, 137] - A Phase 1b study of VK0214 in patients with X-linked adrenoleukodystrophy is ongoing, with data expected in the second quarter of 2024[7] Financial Status - As of December 31, 2023, the company's cash and short-term investments totaled $362.079 million[141] - The company's cash burn year-to-date as of December 31, 2023, was $76.835 million[141] - A follow-on offering in the first quarter of 2024 yielded gross proceeds of $630 million[141]